Nxera Pharma Co Ltd (4565)

Tokyo

Currency in JPY

934.0

+66.0(+7.60%)

Closed·06:30:29

Fair Value

Unlock Value

Day's Range

920.0

962.0

52 wk Range

668.0

1,048.0

Nxera Pharma (4565) Income Statement & Profits

Assess the Nxera Pharma Income Statement (earnings report), showing the company's financial performance from operating and non operating activities such as revenue, expenses and income. Check assets and liabilities, diluted earnings per share (EPS), and net income after taxes for the last 4 periods (either quarterly or annually).

Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.

Period Ending:

2017

31/03

2018

31/03

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

aa.aa

17,712

15,569

12,766

28,835

29,615

Total Revenues Growth

aa.aa

+100.32%

-12.1%

-18%

+125.87%

+2.71%

Cost Of Revenues

aa.aa

933

926

3,102

7,616

8,198

Gross Profit

aa.aa

16,779

14,643

9,664

21,219

21,417

Gross Profit Growth

aa.aa

+107.64%

-12.73%

-34%

+119.57%

+0.93%

Gross Profit Margin %

aa.aa

94.73%

94.05%

75.7%

73.59%

72.32%

Other Operating Expenses, Total

aa.aa

9,869

11,831

20,063

27,843

29,880

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+36.56%	+19.88%	+69.58%	+38.78%	+7.32%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5,931	7,454	10,075	11,816	14,466
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	3,138	3,535	8,167	12,924	15,225
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-2	0	23	12	189

Operating Income

aa.aa

6,910

2,812

-10,399

-6,624

-8,463

Operating Income Growth

aa.aa

+709.13%

-59.31%

-469.81%

+36.3%

-27.76%

EBIT Margin %

aa.aa

39.01%

18.06%

-81.46%

-22.97%

-28.58%

Net Interest Expenses

aa.aa

-514

-437

438

709

-6,488

Net Interest Expenses Growth

aa.aa

-198.84%

+14.98%

+200.23%

+61.87%

-1,015.09%

Interest Expense, Total

aa.aa

-518

-673

-787

-769

-7,475

Interest And Investment Income

aa.aa

236

1,225

1,478

987

Other Non Operating Expenses, Total

aa.aa

-3,033

580

-611

1,315

EBT, Excl. Unusual Items

aa.aa

3,363

2,955

-10,572

-4,600

-14,950

Gain (Loss) On Sale Of Assets

aa.aa

-62

-63

Other Unusual Items, Total

aa.aa

-3,138

EBT, Incl. Unusual Items

aa.aa

433

1,078

-10,680

-4,662

-14,950

EBT, Incl. Unusual Items Growth

aa.aa

-73.3%

+148.96%

-1,090.72%

+56.35%

-220.68%

EBT, Incl. Unusual Items Margin

aa.aa

2.44%

6.92%

-83.66%

-16.17%

-50.48%

Income Tax Expense

aa.aa

-584

696

-3,487

176

-2,420

Net Income to Company

aa.aa

1,017

382

-7,193

-4,838

-12,530

Minority Interest

aa.aa

Net Income

aa.aa

1,017

382

-7,193

-4,838

-12,530

Net Income Growth

aa.aa

-31.24%

-62.44%

-1,982.98%

+32.74%

-158.99%

Net Income Margin %

aa.aa

5.74%

2.45%

-56.34%

-16.78%

-42.31%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

1,017

382

-7,193

-4,838

-12,530

Basic EPS - Continuing Operations

aa.aa

12.53

4.67

-87.17

-53.92

-138.8

Basic EPS - Continuing Operations Growth

aa.aa

-33.31%

-62.71%

-1,966.29%

+38.15%

-157.43%

Diluted EPS - Continuing Operations

aa.aa

12.4

4.63

-87.18

-53.92

-138.8

Diluted EPS - Continuing Operations Growth

aa.aa

-33.3%

-62.66%

-1,982.94%

+38.15%

-157.41%

Basic Weighted Average Shares Outstanding

aa.aa

81.19

81.79

82.52

89.73

90.28

Diluted Weighted Average Shares Outstanding

aa.aa

82.01

82.59

82.52

89.73

90.28

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

8,188

4,157

-7,921

-2,640

-4,097

EBITDA Growth

aa.aa

+271.51%

-49.23%

-290.55%

+66.67%

-55.19%

EBITDA Margin %

aa.aa

46.23%

26.7%

-62.05%

-9.16%

-13.83%

EBIT

aa.aa

6,910

2,812

-10,399

-6,624

-8,463

* In Millions of JPY (except for per share items)

FAQ

What was Nxera Pharma’s revenue at year end?

At the end of the last reported fiscal year, Nxera Pharma (4565) recorded total revenue of 29,615.0.

How much revenue did Nxera Pharma report in the most recent quarter?

In its most recent quarterly earnings report, Nxera Pharma posted revenue of 7,767.0.

What was Nxera Pharma’s net income for the year?

For the full year, Nxera Pharma reported net income of -12,530.0.

How much net income did Nxera Pharma post in the last quarter?

In the most recent quarter, Nxera Pharma (4565) posted net income of -7,721.0.

What was Nxera Pharma’s gross profit for the year?

Gross profit for the year was reported at 21,417.0.

How much gross profit did Nxera Pharma generate last quarter?

Nxera Pharma recorded gross profit of 5,715.0 in its latest quarterly report.

What was Nxera Pharma’s annual operating income?

For the full year, Nxera Pharma (4565) reported operating income of -8,463.0.

What was Nxera Pharma’s operating income last quarter?

Quarterly operating income was -2,556.0.

What was Nxera Pharma’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -1,473.0.

What was the quarter-over-quarter change in EBITDA for Nxera Pharma?

EBITDA changed by 28.0% compared to the last quarter.

What is Nxera Pharma’s most recent gross profit margin?

The latest reported gross profit margin for Nxera Pharma (4565) is 73.6%.

What is Nxera Pharma’s most recent net income margin?

Net income margin based on recent financials is -99.4%.

What is Nxera Pharma’s most recent EBIT margin?

Nxera Pharma reported an EBIT margin of -32.9% based on current figures.

How did Nxera Pharma’s revenue change compared to the previous quarter?

Revenue changed by 15.0% compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Nxera Pharma?

In the latest quarter 2026, gross profit changed by 40.0% from the previous quarter.

FTSE 100

10,473.69

+27.34

+0.26%

DAX

24,800.91

-113.97

-0.46%

Euro Stoxx 50

5,978.75

-6.48

-0.11%

S&P 500

6,836.17

+3.41

+0.05%

Nikkei 225

56,806.41

-135.56

-0.24%

Dow Jones

49,500.93

+48.95

+0.10%

FTSE 100 Futures

10,438.10

+5.6

+0.05%

Market Movers

Name	Last	Chg. %	Vol.
HSBC	1,251.20	+1.02%	17.07M
Relx	2,174.00	-3.68%	10.47M
GSK plc	2,184.00	+0.88%	8.11M
Reckitt Benckiser	6,420.0	-0.74%	3.66M
Unilever	5,420.0	-0.22%	2.84M
Rio Tinto PLC	7,111.0	-1.06%	2.61M
AstraZeneca	15,160.0	+0.28%	2.08M

Name	Last	Chg. %	Vol.
Idex ASA	5.2500	+465.73%	293.00
National Bank of Greece	14.310	+415.30%	200.00
KGHM Polska Miedz	305.80	+170.98%	177.00
Scandi Standard publ AB	128.40	+140.00%	789.00
Kitron	94.45	+131.21%	2.91K
Gedeon Richter	11,624.3	+130.64%	9.83K
COSMO Pharma	115.60	+112.11%	2.17K

Name	Last	Chg. %	Vol.
Soltec Power	0.54	-82.58%	1.68K
Next Biometrics	1.00	-76.91%	3.00K
REC Silicon	0.44	-62.71%	7.15K
MindMaze Therapeutics Holding	1.06	-62.28%	1.05K
Kinnevik B	64.28	-61.65%	387.62K
Transgene	0.854	-57.83%	297.00
SkinBioTherapeutics	6.00	-51.53%	33.14M

Trending Stocks

Name	Last	Chg. %	Vol.
Rolls-Royce Holdings	1,298.00	+2.12%	11.51M
Barclays	461.05	+1.55%	29.72M
BAE Systems	2,029.00	+3.10%	6.00M
KEFI Minerals	1.935	+4.60%	237.14M
EQTEC PLC	0.0490	+15.29%	631.53M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaa Aaaaa A	1,569.00	+42.78%	2,240.22
Aaaaaaaaaaaa Aaa	465.75	+41.92%	660.99
A Aa Aaaaa	2,108.0	+35.89%	2,864.6
Aaaaa	788.20	+32.64%	1,045.47
Aaaa Aaaaa	2,184.00	+31.77%	2,877.86
A Aaa Aaaaaaaaaaaaaa	2,174.00	+31.11%	2,850.33
Aaaaaaaaa	3,497.00	+31.01%	4,581.42

Name	Last	Upside	Fair Value
Aaaa Aaaaa A	1,569.00	+42.78%	2,240.22
Aaaaaaaaaaaa Aaa	465.75	+41.92%	660.99
A Aa Aaaaa	2,108.0	+35.89%	2,864.6
Aaaaa	788.20	+32.64%	1,045.47
Aaaa Aaaaa	2,184.00	+31.77%	2,877.86
A Aaa Aaaaaaaaaaaaaa	2,174.00	+31.11%	2,850.33
Aaaaaaaaa	3,497.00	+31.01%	4,581.42

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Nxera Pharma Co Ltd (4565)

Nxera Pharma (4565) Income Statement & Profits

FAQ

What was Nxera Pharma’s revenue at year end?

How much revenue did Nxera Pharma report in the most recent quarter?

What was Nxera Pharma’s net income for the year?

How much net income did Nxera Pharma post in the last quarter?

What was Nxera Pharma’s gross profit for the year?

How much gross profit did Nxera Pharma generate last quarter?

What was Nxera Pharma’s annual operating income?

What was Nxera Pharma’s operating income last quarter?

What was Nxera Pharma’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Nxera Pharma?

What is Nxera Pharma’s most recent gross profit margin?

What is Nxera Pharma’s most recent net income margin?

What is Nxera Pharma’s most recent EBIT margin?

How did Nxera Pharma’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for Nxera Pharma?

Trending Stocks